Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation

[1]  W. Gilewski,et al.  The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  M. M. Mohamed Ibrahim,et al.  Levosimendan for VA‐ECMO weaning: the silver lining , 2021, ESC Heart Failure.

[3]  S. Silvetti,et al.  Effect of Levosimendan Treatment in Pediatric Patients With Cardiac Dysfunction: An Update of a Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2021, Journal of cardiothoracic and vascular anesthesia.

[4]  B. Bouhemad,et al.  Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial , 2021, ESC heart failure.

[5]  S. Ricksten,et al.  Effects of levosimendan on renal blood flow and glomerular filtration in patients with acute kidney injury after cardiac surgery: a double blind, randomized placebo-controlled study , 2021, Critical Care.

[6]  W. Ho,et al.  Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study , 2021, Annals of Intensive Care.

[7]  K. Caliskan,et al.  The Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management and Outcome: A Systematic Review and Meta-Analysis. , 2021, Journal of cardiothoracic and vascular anesthesia.

[8]  Yinan Li,et al.  Effect of Prophylactic Levosimendan on All-Cause Mortality in Pediatric Patients Undergoing Cardiac Surgery—An Updated Systematic Review and Meta-Analysis , 2020, Frontiers in Pediatrics.

[9]  P. Mason.  Levosimendan , 2020, Reactions Weekly.

[10]  Jonathan Chauvin,et al.  Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil , 2020, CPT: pharmacometrics & systems pharmacology.

[11]  F. Wang,et al.  Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial , 2019, Critical Care.

[12]  D. Tibboel,et al.  Drug Disposition and Pharmacotherapy in Neonatal ECMO: From Fragmented Data to Integrated Knowledge , 2019, Front. Pediatr..

[13]  R. Persichini,et al.  Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit , 2019, Annals of Intensive Care.

[14]  Monika Tukacs.  Pharmacokinetics and Extracorporeal Membrane Oxygenation in Adults: A Literature Review , 2018, AACN advanced critical care.

[15]  H. Cao,et al.  Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis. , 2017, Medicina intensiva.

[16]  S. Dowd,et al.  Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers , 2016, Gut microbes.

[17]  Jeremy K Nicholson,et al.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity. , 2017, Translational research : the journal of laboratory and clinical medicine.

[18]  Robert H. Bartlett,et al.  Development and validation of the pediatric risk estimate score for children using extracorporeal respiratory support (Ped-RESCUERS) , 2016, Intensive Care Medicine.

[19]  D. Gonzalez,et al.  Clinical Pharmacology Studies in Critically Ill Children , 2016, Pharmaceutical Research.

[20]  John F. Fraser,et al.  Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models , 2015, Critical Care.

[21]  J. Fraser,et al.  Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study , 2015, Critical Care.

[22]  F. Cabañas,et al.  Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery , 2013, Pediatric Research.

[23]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.

[24]  D. Tibboel,et al.  Determinants of drug absorption in different ECMO circuits , 2010, Intensive Care Medicine.

[25]  P. Pentikäinen,et al.  Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment , 2008, Journal of clinical pharmacology.

[26]  P. Pentikäinen,et al.  Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[28]  L. Lehtonen,et al.  Clinical Pharmacology of Levosimendan , 2007, Clinical pharmacokinetics.

[29]  K. Csapo,et al.  Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. , 2006, Cardiovascular drug reviews.

[30]  U. Pesonen,et al.  Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  P. Pentikäinen,et al.  Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. , 2004, British journal of clinical pharmacology.

[32]  I. Édes,et al.  The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. , 2004, European journal of pharmacology.

[33]  Mats O Karlsson,et al.  Population pharmacokinetics of levosimendan in patients with congestive heart failure. , 2003, British journal of clinical pharmacology.

[34]  Honghui Zhou.  Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles , 2003, Journal of clinical pharmacology.